We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
Cap. Flow
+$85.4M
Cap. Flow %
7.49%
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.8M
2
HUM icon
Humana
HUM
+$19.1M
3
XLRN
Acceleron Pharma
XLRN
+$15.3M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$13.2M
5
MDVN
MEDIVATION, INC.
MDVN
+$12.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$68.4M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.9M
3
BAX icon
Baxter International
BAX
+$10.1M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$8.54M
5
NVRO
NEVRO CORP.
NVRO
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.87%
2 Consumer Staples 0.6%
3 Consumer Discretionary 0.11%
4 Industrials 0.04%
5 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDA icon
26
Sonida Senior Living
SNDA
$1.91B
$10.1M 0.88%
36,309
+4,062
+13% +$1.06M
CTMX icon
27
CytomX Therapeutics
CTMX
$723M
$9.57M 0.84%
742,021
+99,974
+16% +$1.39M
PFNX
28
DELISTED
Pfenex Inc.
PFNX
$9.45M 0.83%
960,877
– –
CDTX
29
DELISTED
Cidara Therapeutics
CDTX
$9.43M 0.83%
37,143
– –
ALDR
30
DELISTED
Alder Biopharmaceuticals
ALDR
$9.18M 0.81%
+375,000
New +$8.68M
RXDX
31
DELISTED
Ignyta, Inc.
RXDX
$9.12M 0.8%
1,347,060
-465,000
-26% -$3.83M
AGTC
32
DELISTED
Applied Genetic Technologies Corporation
AGTC
$9.1M 0.8%
650,591
-210,922
-24% -$3.09M
ASRT
33
DELISTED
Assertio
ASRT
$9.05M 0.79%
10,833
+2,500
+30% +$2.32M
BAX icon
34
Baxter International
BAX
$13.7B
$9.04M 0.79%
220,000
-265,000
-55% -$10.1M
RGNX icon
35
Regenxbio
RGNX
$619M
$8.91M 0.78%
825,396
+46,183
+6% +$591K
ZYNE
36
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$8.03M 0.7%
849,350
+290,904
+52% +$2.35M
AKBA icon
37
Akebia Therapeutics
AKBA
$251M
$7.79M 0.68%
865,000
+605,000
+233% +$4.91M
VBIV
38
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$7.66M 0.67%
108,679
– –
EGRX
39
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$7.58M 0.67%
187,215
+54,070
+41% +$3.43M
VCEL icon
40
Vericel Corp
VCEL
$2.17B
$7.31M 0.64%
1,247,312
+941,650
+308% +$2.64M
BPMC
41
DELISTED
Blueprint Medicines
BPMC
$7.3M 0.64%
404,404
– –
BAX icon
42
CALL
Baxter International
BAX
$13.7B
$7.17M 0.63%
175,400
+75,400
+75% +$2.87M
EYPT icon
43
EyePoint Inc
EYPT
$430M
$7.14M 0.63%
266,500
+225,000
+542% +$7.11M
ACAD icon
44
Acadia Pharmaceuticals
ACAD
$5.1B
$7.14M 0.63%
255,240
+10,000
+4% +$218K
NEPT
45
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$6.75M 0.59%
4,822
+36
+0.8% +$53.9K
EVH icon
46
Evolent Health
EVH
$556M
$6.54M 0.57%
618,930
+471,330
+319% +$4.87M
NVO
47
Novo Nordisk
NVO
$209B
$6.32M 0.55%
233,320
+214,240
+1,123% +$5.74M
MRTX
48
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.84M 0.51%
+273,000
New +$6.1M
HZNP
49
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.8M 0.51%
+350,000
New +$6.12M
NVRO
50
CALL
DELISTED
NEVRO CORP.
NVRO
$5.63M 0.49%
+100,000
New +$5.9M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $85.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $12.9M trimmed.

  • Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
  • Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $12.9M.
  • Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
  • Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
  • Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.

Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.